Phacilitate Leaders World

Sponsors & Exhibitors

Evidera | PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. PPD accelerates customers’ promising medicines from early development through regulatory approval and market access. Committed to global operational excellence, we deploy an exceptional span and quality of solutions, generating evidence to demonstrate effectiveness, safety and value. PPD is dedicated to helping customers deliver life-changing therapies to patients by bending the cost and time curve of drug development and optimizing value. Evidera, a PPD business unit, is a leading provider of evidence-based solutions to demonstrate the real-world effectiveness, safety and value of health care products, helping biopharmaceutical, biotechnology and medical device companies generate the evidence needed to optimize the market access and commercial potential of their products.

Visit Website
View all Sponsors & Exhibitors
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman